stockrow
Saturday 7 November 2026
Export AVXL’s income statement to Excel — free account
Anavex Life Sciences Corp.
AVXL Healthcare Biotechnology
- EPS
- +150.0%
- Free cash flow
- +27.0%
Quarter to June 2026, against a year earlier
1.15
0.04
+3.60%
Follow AVXL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 349 | 349 | 349 | 0.0% | |
| Gross margin, % | 0.00 | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (48) | (43) | (46) | (13) | +13.6% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (48) | (43) | (46) | (13) | +13.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.42) | (0.33) | (0.39) | (0.54) | (0.45) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) | (0.15) | +2.8% | ||||||
| Cash flow | (0.26) | (0.22) | (0.28) | (0.38) | (0.37) | (0.44) | (0.32) | (0.35) | (0.37) | (0.46) | (0.32) | +6.4% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.26) | (0.22) | (0.28) | (0.38) | (0.37) | (0.44) | (0.32) | (0.35) | (0.37) | (0.46) | (0.32) | +6.4% | ||||||
| Book value | 0.18 | 0.59 | 0.50 | 0.41 | 0.47 | 2.16 | 1.85 | 1.78 | 1.44 | 1.11 | 1.21 | +22.5% | ||||||
| Shares, m | 35 | 41 | 45 | 49 | 58 | 70 | 77 | 80 | 83 | 85 | 90 | +10.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (9) | (9) | (13) | (19) | (21) | (30) | (24) | (28) | (31) | (39) | (29) | +17.4% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | (9) | (9) | (13) | (19) | (21) | (30) | (24) | (28) | (31) | (39) | (29) | +17.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 6 | 24 | 22 | 20 | 27 | 151 | 142 | 142 | 120 | 95 | 112 | +35.3% | |||||
| Net debt | (9) | (27) | (23) | (22) | (29) | (152) | (149) | (151) | (132) | (103) | (118) | +30.7% | ||||||
| Shareholders’ equity | 6 | 24 | 22 | 20 | 27 | 151 | 142 | 142 | 120 | 95 | 112 | +35.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (118.04) | (72.10) | (63.85) | (102.05) | (87.79) | (38.65) | (30.53) | (30.94) | (29.66) | (38.75) | (11.70) | +79.3 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (154.17) | (88.09) | (74.08) | (123.42) | (110.59) | (42.58) | (32.71) | (33.41) | (32.81) | (43.11) | (12.80) | +111.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 10 | 10 | 13 | 16 | 20 | 25 | 38 | 40 | 42 | 34 | — | +14.6% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Anavex Life Sciences Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | $106.9M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| VYGR Voyager Therapeutics, Inc. | $106.0M | — (loss-making) | — (loss-making) | −69.97% (below 0%: shrinking) | n/m | +37.08% (above 0%: growing) | 100.00% | (658.25%) | Compare |
| ANIX ANIXA BIOSCIENCES INC | $105.3M | — (loss-making) | — (loss-making) | 0.00% | n/m | −17.14% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NBP NovaBridge Biosciences | $105.3M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $102.9M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | |
| HURA TuHURA Biosciences, Inc. | $102.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OKUR OnKure Therapeutics, Inc. | $102.3M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMUX Immunic, Inc. | $99.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| Median of peers | $104.0M | — | — | −79.25% | — | −21.96% | 0.00% | 0.00% |